Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

NEWLINK TECHNOLOGY INC.
新紐科技有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9600)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

FINANCIAL HIGHLIGHTS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**85,035**	133,740
Gross profit	**17,589**	24,066
Loss before tax	**(32,838)**	(64,609)
Income tax expense	**(42)**	(24)
Loss for the period	**(32,880)**	(64,633)

	As at 30 June 2026	As at 31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Total assets	**673,172**	748,278
Total liabilities	**155,404**	206,483
Total equity	**517,768**	541,795

In this announcement, “we”, “us” and “our” refer to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of Newlink Technology Inc. (the “**Company**” or “**Newlink Technology**”, together with its subsidiaries, the “**Group**”) is pleased to announce the unaudited consolidated results of the Group for the six months ended 30 June 2026 (the “**Reporting Period**”), together with the comparative figures for the corresponding period in 2025.

* *For identification purposes only*

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026

	Notes	For the six months ended 30 June 2026 RMB'000 (Unaudited)	2025 RMB'000 (Unaudited)
Revenue	3	**85,035**	133,740
Cost of sales and services rendered	6	**(67,446)**	(109,674)
Gross profit		**17,589**	24,066
Other income and gains	4	**3,741**	3,645
Change in fair value of equity investments at fair value through profit or loss		**(3,609)**	(18,218)
Change in fair value of contingent consideration		**–**	1,576
Selling and distribution expenses		**(9,128)**	(9,672)
Administrative expenses		**(20,954)**	(23,728)
Research and development expenses		**(18,128)**	(27,627)
Allowance for expected credit losses on trade receivables, contract assets and other receivables, net		**–**	(10,472)
Other expenses		**(296)**	(2,012)
Finance costs	5	**(631)**	(539)
Share of results of an associate		**(1,422)**	(1,628)
Loss before tax	6	**(32,838)**	(64,609)
Income tax expense	7	**(42)**	(24)
Loss for the period		**(32,880)**	(64,633)

	Notes	For the six months ended 30 June **2026** *RMB'000* (Unaudited)	2025 *RMB'000* (Unaudited)
Other comprehensive (loss) income:			
Item that will not be reclassified to profit or loss:			
Exchange differences arising on translation from functional currency to presentation currency		**(7,101)**	(3,958)
Item that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		**115**	(566)
Other comprehensive loss for the period, net of tax		**(6,986)**	(4,524)
Total comprehensive loss for the period		**(39,866)**	(69,157)
(Loss) Profit for the period attributable to:			
Owners of the Company		**(32,884)**	(64,378)
Non-controlling interests		**4**	(255)
		(32,880)	(64,633)
Total comprehensive (loss) income for the period attributable to:			
Owners of the Company		**(39,870)**	(68,902)
Non-controlling interests		**4**	(255)
		(39,866)	(69,157)
		RMB cents	*RMB cents*
Loss per share			
Basic and diluted	*9*	**(3.34)**	(6.86)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2026

	Notes	30 June 2026 RMB'000 (Unaudited)	31 December 2025 RMB'000 (Audited)
Non-current assets			
Investment properties		**9,692**	9,692
Property and equipment	*10*	**10,062**	10,724
Right-of-use assets		**6,727**	8,590
Intangible assets	*11*	**55,544**	63,697
Goodwill		**36,724**	36,724
Investment in an associate		**2,474**	3,896
Equity investments at fair value through profit or loss		**13,300**	13,300
Long-term deposits and prepayments	*14*	**5,866**	8,555
Deferred tax assets		**381**	381
		140,770	155,559
Current assets			
Inventories		**1,414**	1,414
Trade receivables	*12*	**187,981**	190,405
Contract assets	*13*	**92,194**	90,867
Equity investments at fair value through profit or loss		**7,900**	11,873
Prepayments, deposits and other receivables	*14*	**7,651**	8,119
Amount due from a related party		**2,228**	2,228
Pledged deposits		**253**	829
Restricted bank balances		**2,195**	3,273
Bank balances and cash		**230,586**	283,711
		532,402	592,719

	Notes	**30 June 2026** ***RMB'000*** **(Unaudited)**	31 December 2025 *RMB'000* (Audited)
Current liabilities			
Trade payables	*15*	**83,696**	121,445
Contract liabilities		**24,220**	17,711
Other payables and accruals	*16*	**18,267**	26,081
Dividends payable	*8*	**6**	6
Interest-bearing bank borrowings	*17*	**20,000**	30,000
Lease liabilities		**4,733**	5,112
Tax payable		**490**	490
		151,412	200,845
Net current assets		**380,990**	391,874
Total assets less current liabilities		**521,760**	547,433
Non-current liabilities			
Lease liabilities		**3,992**	5,638
Net assets		**517,768**	541,795
Capital and reserves			
Share capital	*18*	**7**	7
Reserves		**517,963**	541,994
Equity attributable to owners of the Company		**517,970**	542,001
Non-controlling interests		**(202)**	(206)
Total equity		**517,768**	541,795

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 June 2026

1. GENERAL INFORMATION

Newlink Technology Inc. (the "**Company**") was incorporated and registered as an exempted company with limited liability in the Cayman Islands under the Companies Law of the Cayman Islands on 8 November 2019 with its shares listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on 6 January 2021. The address of the Company's registered office is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. The address of the Company's principal place of business in Hong Kong is Unit 06 on 20th Floor of Harbour Centre, No. 25 Harbour Road, Wan Chai, Hong Kong, and the headquarters and principal place of business in the People's Republic of China (hereafter, the "**PRC**") is 5/F., Tower A, Xueqing Jiachuang Building, Xueqing Road, Haidian District, Beijing, the PRC.

The Company is an investment holding company and its subsidiaries (collectively referred to as the "**Group**") are principally engaged in the business of software development and maintenance in the PRC.

In the opinion of the Directors of the Company, the immediate holding company and the ultimate holding company of the Company is Nebula SC Holdings Limited, a company incorporated in British Virgin Islands, while the ultimate beneficial owner of the Company is Mr. Zhai Shuchun ("**Mr. Zhai**"), the executive director of the Company.

2. BASIS OF PREPARATION

The Directors are responsible for the preparation of the Group's interim condensed consolidated financial information. These interim condensed consolidated financial information have been prepared in accordance with Hong Kong Accounting Standard ("**HKAS**") 34 "Interim Financial Reporting", issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**") and the applicable disclosure requirements of Appendix D2 to the Rules Governing the Listing of Securities on the Stock Exchange. These interim condensed consolidated financial information should be read in conjunction with the 2025 annual financial statements (the "**2025 Annual Report**"). The accounting policies adopted in preparing the interim condensed consolidated financial information for the six months ended 30 June 2026 are consistent with those in the preparation of the Group's 2025 Annual Report, except for the adoption of the revised HKFRS Accounting Standards which are relevant to the Group's operation and are effective for the Group's financial year beginning on 1 January 2026 as described below.

Adoption of revised HKFRS Accounting Standards

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Annual Improvements to HKFRS Accounting Standards	Volume 11
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity

The adoption of revised HKFRS Accounting Standards did not result in substantial changes to the Group's accounting policies and amounts reported for the current period and prior years.

Future changes in HKFRS Accounting Standards

At the date of authorisation of the Group's interim condensed consolidated financial information, the HKICPA has issued a number of new/revised HKFRS Accounting Standards that are not yet effective for the current period, which the Group has not early adopted.

The Directors have assessed the possible impact on the future adoption of the new/revised HKFRS Accounting Standards and estimate that the amendments do not have any significant impact on the interim condensed consolidated financial statements.

3. REVENUE AND SEGMENT INFORMATION

The Group's operating activities are attributable to a single operating and reporting segment primarily on the provision of IT solution services in the PRC. This operating segment has been identified on the basis of internal management reports reviewed by the chief operating decision-makers (the "**CODM**"), being the executive Directors of the Company. The CODM mainly reviews revenue derived from provision of software development services, technical and maintenance services and sale of standard software, which are measured in accordance with the Group's accounting policies. The financial information reported to the CODM is reflected through the overall operating performance of the Group for resource allocation and performance evaluation. Accordingly, no segment information is presented.

Information about major customers

Aggregated revenue of approximately RMB39,938,000 (30 June 2025: approximately RMB65,310,000) was derived from the following single customers, which individually accounted for more than 10% of the Group's total revenue.

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Customer 1	**15,761**	18,519
Customer 2	*	16,920
Customer 3	*	15,053
Customer 4	*	14,818
Customer 5	**15,511**	*
Customer 6	**8,666**	*

* The correspondence revenue of the customer is not disclosed as the revenue individually did not account for 10% or more of the Group's revenue for the respective period.

Revenue from contracts with customers

Disaggregated revenue information

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Types of goods or services		
Software development services	**71,031**	118,661
Technical and maintenance services	**13,246**	12,839
Sale of standard software	**758**	2,240
Total revenue from contracts with customers	**85,035**	133,740
Timing of revenue recognition		
Goods transferred at a point in time	**758**	2,240
Services transferred over time	**84,277**	131,500
Total revenue from contracts with customers	**85,035**	133,740

4. OTHER INCOME AND GAINS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Bank interest income	**2,991**	1,822
Value Added Tax ("**VAT**") refunds and other tax subsidies *(Note)*	**455**	1,018
Others	**295**	805
	3,741	3,645

Note: Refunds of VAT on software products represent the refund upon payment of VAT with respect to the portion of any effective VAT rate in excess of 3% in respect of software product sales of the Group pursuant to the principles of the State Council document entitled "Certain Policies to Encourage the Development of Software Enterprise and the IC Industry" and the approval of the state taxation authorities.

5. FINANCE COSTS

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Interest expense on interest-bearing bank borrowings	**363**	194
Interest on lease liabilities	**268**	345
	631	539

6. LOSS BEFORE TAX

This is arrived at after charging (crediting):

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Cost of inventories sold	**618**	2,017
Cost of sales and services rendered	**66,828**	107,657
	67,446	109,674
Research and development expenses:		
Amortisation of deferred development costs *(Note (i))*	**9,904**	16,218
Amortisation of software licenses *(Note (i))*	**2,941**	4,892
Current year expenditure	**5,283**	6,517
	18,128	27,627
Employee benefit expense (including Directors' and chief executive's remuneration):		
Wages and salaries	**61,295**	66,798
Pension scheme contributions (defined contribution scheme)	**11,873**	11,667
Termination benefits	**2,041**	1,618
	75,209	80,083
Depreciation of property and equipment	**702**	1,203
Depreciation of right-of-use assets	**2,242**	2,483
Amortisation of intangible assets *(Note (i))*	**15,773**	23,698
Allowance for expected credit losses ("**ECL**") on trade receivables	–	10,314
Allowance for ECL on contract assets	–	163
Reversal of allowance for ECL of other receivables	–	(5)
Foreign exchange differences, net	**296**	124

Note:

(i) The amortisation of deferred development costs and software licenses classified under research and development expenses is included in the amortisation of intangible assets. The amortisation of intangible assets for the period is included in cost of sales, selling and distribution expenses, administrative expenses and research and development expenses in the interim condensed consolidated statement of profit or loss and other comprehensive income.

7. INCOME TAX EXPENSE

The amount of taxation in the interim condensed consolidated statement of profit or loss and other comprehensive income represents:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Current income tax: PRC enterprise income tax	**42**	24
Income tax expense	**42**	24

(i) Cayman Islands

The Company was incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands and accordingly is not subject to income tax.

(ii) Hong Kong

Hong Kong Profits Tax has been provided at the rate of 16.5% (30 June 2025: 16.5%) on the Group's estimated assessable profits arising from Hong Kong during the period. The Group had incurred a loss for taxation purposes for the six months ended 30 June 2026 and 2025.

(iii) PRC

The income tax provision of the Group in respect of its operations in the PRC was subject to statutory tax rate of 25% on the assessable profits for the six months ended 30 June 2026 (30 June 2025: 25%), except for certain subsidiaries which obtained the "High and New Technology Enterprise" qualification with preferential tax rate of 15% (30 June 2025: 15%).

(iv) Singapore

Singapore Corporate Income Tax is charged at 17% (30 June 2025: 17%) on the Group's estimated assessable profits arising from Singapore during the period. The Group had incurred a loss for taxation purposes for the six months ended 30 June 2026 and 2025.

(v) **USA**

US corporation is subject to two level of taxes. Corporation is taxed on its earnings, and when the corporate earnings are distributed to the shareholders as dividend, the shareholders need to pay tax on the dividend received. Corporate income tax is imposed at the federal and state level on all entities treated as corporation. The federal corporate tax rate is 21% while the state corporate tax rate is varied by states for the six months ended 30 June 2026 and 2025.

8. DIVIDENDS

The Board of Directors does not recommend the payment of an interim dividend for the six months ended 30 June 2026 (30 June 2025: nil).

9. LOSS PER SHARE

The basic loss per share is calculated by dividing the loss attributable to owners of the Company by the weighted average number of ordinary shares issued during the six months ended 30 June 2026.

The Company has no potential dilutive ordinary shares in issue during the six months ended 30 June 2026 and 2025.

The calculations of basic and diluted loss per share are based on:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Loss		
Loss for the period attributable to owners of the Company for the purpose of basic and diluted loss per share	**(32,884)**	(64,378)

	Number of Shares	
	2026	2025
Number of Shares		
Weighted average number of ordinary shares for the purpose of calculation of basic and diluted loss per share	**984,197,813**	937,864,480

10. PROPERTY AND EQUIPMENT

During the six months ended 30 June 2026, the Group acquired property and equipment with a cost of approximately RMB54,000 (30 June 2025: approximately RMB298,000), including electronic equipment and furniture and leasehold improvements (30 June 2025: electronic equipment and furniture and leasehold improvements).

11. INTANGIBLE ASSETS

During the six months ended 30 June 2026, additions and amortisation of intangible assets were approximately RMB7,620,000 (30 June 2025: approximately RMB12,826,000) and approximately RMB15,773,000 (30 June 2025: approximately RMB23,698,000) respectively. As at 30 June 2026, the carrying amount of the intangible assets of the Group included deferred development costs that are not yet available for use of approximately RMB nil (31 December 2025: approximately RMB8,839,000). The Directors of the Company have not identified any significant adverse change in the projects related to the intangible assets included deferred development costs that are not yet available for use for the six months ended 30 June 2026 as compared to the year ended 31 December 2025.

12. TRADE RECEIVABLES

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Trade receivables	**289,582**	292,006
Less: allowance for ECLs	**(101,601)**	(101,601)
	187,981	190,405

The Group's trading terms with its customers are mainly on credit. For software development services, the credit period granted to the customers is normally 30 to 180 days upon issuance of invoice and receipt of acceptance from customers during the course of contracts. The forms of acceptance evidenced the satisfaction from the customers of the progress of completion. For the sale of standard software, the credit period granted to the customers is normally 30 to 180 days after the goods were accepted by the customers, except for new customers where payment in advance is normally required. For technical and maintenance services, the credit period granted to the customers is normally due upon completion of the service or 30 to 180 days from the date of billing.

The following is an ageing analysis of the trade receivables as at the end of reporting periods, based on the recognition date of gross trade receivables and net of allowance for ECLs:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 90 days	**30,518**	70,270
91 days to 180 days	**15,265**	8,958
181 days to 365 days	**42,253**	36,790
1 year to 2 years	**47,825**	45,423
2 years to 3 years	**31,854**	18,313
Over 3 years	**20,266**	10,651
	187,981	190,405

13. CONTRACT ASSETS

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Contract assets	**92,879**	91,552
Less: allowance for ECLs	**(685)**	(685)
	92,194	90,867

14. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Prepayments	**7,016**	9,899
Rental deposits	**1,467**	1,398
Deposits and other receivables	**5,034**	5,377
	13,517	16,674
Classified as:		
Current assets	**7,651**	8,119
Non-current assets	**5,866**	8,555
	13,517	16,674

15. TRADE PAYABLES

The aging analysis of trade payables at the end of reporting periods, based on the invoice date is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Within 90 days	**244**	57,278
91 days to 180 days	**859**	213
181 days to 365 days	**42,353**	30,076
1 year to 2 years	**10,492**	10,908
Over 2 years	**29,748**	22,970
	83,696	121,445

The credit term granted by the trade creditors is generally 120 days (2025: 120 days).

16. OTHER PAYABLES AND ACCRUALS

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Other payables	**765**	2,699
Accrued staff costs	**11,595**	16,611
Other tax payables	**5,907**	6,771
	18,267	26,081

17. INTEREST-BEARING BANK BORROWINGS

	30 June 2026 (Unaudited)			31 December 2025 (Audited)		
	Effective interest rate	**Maturity in**	***RMB'000***	Effective interest rate	Maturity in	*RMB'000*
Current:						
Bank loans – unsecured and unguaranteed	**3.2%**	**2026**	**20,000**	3.2%-3.6%	2026	30,000

18. SHARE CAPITAL

	30 June 2026 (Unaudited)			31 December 2025 (Audited)		
	No. of shares	***US$***	***Equivalent to RMB'000***	*No. of shares*	*US$*	*Equivalent to RMB'000*
Authorised:						
Ordinary shares of US$0.000001 each	**50,000,000,000**	**50,000**		50,000,000,000	50,000	
Issued and fully paid:						
At the beginning of the period/year	**943,817,280**	**944**	**7**	943,817,280	944	7
New shares issued	**60,000,000**	**60**	**–***	–	–	–
At the end of the reporting period	**1,003,817,280**	**1,004**	**7**	943,817,280	944	7

On 11 February 2026, the Company issued a total of 60,000,000 new ordinary shares under general mandate at the subscription price of HK$0.3 per share. The net proceeds from the subscription after deducting related expenses were approximately HK$17,909,000 (equivalent to approximately RMB15,839,000), which intended to replenish general working capital of the Group. These shares rank pari passu with the existing shares in all respects.

* Less than RMB1,000.

BUSINESS REVIEW AND OUTLOOK

Overview

As a leading technology-driven IT solution service provider in China with the development of proprietary software products as its core, the Group has long been focusing on the implementation of cutting-edge technologies such as artificial intelligence, big data analytics and large model applications, providing high-value-added customised and standardised integrated digital services to customers across industries including finance, healthcare, transportation, logistics, energy and education.

The Group remains committed to technological innovation. Leveraging its proprietary product portfolio, including Robotic Process Automation (RPA), medical and healthcare big data intelligent management, smart new energy stations, multimodal medical document generation, and intelligent risk control semantic analysis, the Group integrates underlying technologies such as data mining, cloud computing, distributed databases, knowledge graphs, deep learning and privacy-preserving computation to deliver integrated solutions tailored to customers' business scenarios and facilitating digital transformation across industries. During the Reporting Period, the Group continued to optimise its business structure, curtail inefficient business investments, and strictly control operating expenses, while simultaneously strengthening its patent portfolio in core technologies within the healthcare and finance sectors, steadily advancing market expansion in the Hong Kong and Asia-Pacific regions and exploring industrial capital collaborations, thereby continuously reinforcing the foundation for long-term development.

Business Review

(I) Macro Operating Environment

In the first half of 2026, the pace of global economic recovery diverged, with geopolitical tensions and offshore financial volatility continuing to bring external uncertainties. While the digital transformation of domestic industries continued to advance, the pace of IT budget deployment by downstream enterprises slowed down, project delivery cycles lengthened, and market competition further intensified. The overall industry environment was characterised by "scarcity of high-quality projects, intensifying low-price homogeneous competition, and customers' cost reduction and expenditure control", placing periodic pressure on IT service providers in terms of order acquisition, revenue scale and collection turnover.

In response to the complex external environment, management proactively adjusted its operating strategy, taking business structure optimisation as the core focus, proactively scaling back projects with low gross margins, long working capital tie-up periods and high collection risks, and concentrating resources on high-value-added, high-cash-flow quality customised solutions, while implementing comprehensive cost control across all dimensions. Against the backdrop of a phased decline in revenue, the Group achieved an improvement in gross margin and a significant narrowing of losses, with operating performance continuing to improve.

(II) Operating Results and Business Structure

For the six months ended 30 June 2026, the Group recorded total revenue of RMB85.0 million, representing a year-on-year decrease of 36.4% from RMB133.7 million in the corresponding period of 2025. The decline in the Group's software development services revenue was a key contributor to the decrease in total revenue, mainly due to the Group's proactive reduction of low-margin software development projects. The Group's revenue was entirely derived from its IT solution services segment, with the performance of the three sub-businesses as follows:

1. Software development services: During the Reporting Period, revenue amounted to RMB71.0 million, representing a significant decrease compared with the corresponding period of last year, and was the core factor driving the revenue decline. Among this, revenue from innovative solutions amounted to RMB42.3 million, accounting for 59.6% of software development revenue. Products related to RPA, intelligent medical quality control, and multimodal medical large models continued to achieve implementation, with the innovative business remaining the Group's strategic development priority.

2. Technical and maintenance services: During the Reporting Period, revenue amounted to RMB13.2 million, accounting for 15.5% of total revenue. The maintenance business maintained a stable base relying on existing customers, with solid cash flow performance.

3. Sales of standard software: During the Reporting Period, revenue amounted to RMB0.8 million, all derived from innovative standardised products in the healthcare sector. The business remained small in scale at this stage, and the Group continued its cultivation and market promotion efforts.

On the cost side, costs contracted in line with business scale, with cost of sales and services amounting to RMB67.4 million, representing a decrease broadly in line with the decline in revenue. During the Reporting Period, the Group's gross profit amounted to RMB17.6 million, representing a decrease from RMB24.1 million in the corresponding period of last year. Gross margin increased from 18.0% in the first half of 2025 to 20.7% for the Reporting Period. The decline in gross profit and the improvement in gross margin were mainly attributable to the effective implementation of the Group's structural adjustment strategy of proactively exiting low-margin projects and concentrating resources on high-value-added businesses.

On the cost control front, the Group implemented rigid budget management across the board, with selling and distribution expenses, administrative expenses and research and development expenses all declining significantly compared with the corresponding period of last year. R&D investment was focused on breakthroughs in core medical patents and technological upgrades in financial algorithms, reducing redundant investment in non-core product lines. On the basis of business structure optimisation and full-chain cost reduction and efficiency enhancement, combined with a year-on-year decrease in losses arising from changes in the fair value of equity investments measured at fair value through profit or loss, and the absence of new provisions for expected credit losses on trade receivables, contract assets and other receivables during the period, the Group's losses narrowed significantly during the period, with a loss of RMB32.9 million recorded for the six months ended 30 June 2026, representing a year-on-year reduction in loss of RMB31.7 million compared with a loss of RMB64.6 million in the first half of 2025, significantly alleviating operating loss pressure.

In terms of assets and liquidity, the Group maintained sufficient liquidity reserves, with cash and bank balances of RMB230.6 million as at the end of the period and interest-bearing bank borrowings of only RMB20.0 million, reflecting a low overall debt pressure. However, the combined scale of trade receivables and contract assets remained relatively high, with significant working capital tie-up, representing the primary liquidity concern for the Group's daily operations. In February 2026, the Group completed a share placement, with the net proceeds used to replenish working capital, further strengthening the liquidity safety buffer and ensuring the stable execution of R&D investment, market expansion and daily operations.

(III) Technology R&D, Intellectual Property and Industry Recognition

The Group consistently adheres to the core strategy of independent R&D, continuously optimize the R&D structure, with a focus on foundational technologies related to artificial intelligence, healthcare big data, privacy-preserving computation and multimodal large models. As at 30 June 2026, the Group held a total of 269 software copyrights, with 8 new software copyrights added during the Reporting Period. During the period, 7 new invention patents in the healthcare field were added, covering core technologies and scenarios including intelligent generation of medical documents, real-time intelligent review of medical records, collaborative modelling of multi-institution healthcare data, and intelligent consultation knowledge graph construction, continuously reinforcing the technological moat in healthcare digitalisation.

During the Reporting Period, the Group's technological strength and brand influence continued to gain industry recognition:

1. In April 2026, the Company was awarded the "Hainuo Award – 2026 Innovation Leading Brand"; in June, it was listed on the "2026 China Fintech Competitiveness TOP100" ranking. At the 15th Finance Summit, the Group and its Chairman and Chief Executive Officer received the "2026 Listed Company Brand Value Model Award" and "2026 Technology Innovation Pioneer" respectively.

2. Beijing Newlink Technology Co., Ltd.* (北京新紐科技有限公司), a subsidiary of the Group, was invited to participate in multiple national-level industry summits, delivered a keynote speech at the Digital and Intelligent Healthcare High-Quality Development Conference, and was elected as a Vice Chairman member of the Second Council of the Hospital Informatization Branch of the National Health Industry Enterprise Management Association, with its industry influence continuously improving. It also participated in the Beijing Listed Company High-Quality Development Conference, actively engaging with industrial investment and financing resources.

(IV) Market Expansion, Industry-University-Research Collaboration and Capital Activities

In terms of regional expansion, the Group continued to cultivate its core financial and healthcare markets in Chinese Mainland, while advancing its Asia-Pacific and Greater Bay Area strategy with Hong Kong as a pivotal hub, extending the established collaboration models with Hong Kong-based financial and retail enterprises and continuing to deliver locally-tailored fintech solutions. Industry-university-research collaboration continued to deepen, leveraging the joint laboratory mechanism with The Hong Kong Polytechnic University to advance the industrialisation of fintech technologies and the cultivation of interdisciplinary talent. On the capital front, the Company successfully completed a share placement in the first half of 2026, raising sufficient working capital and optimising its cash flow reserves.

(V) Internal Management, Risk and Sustainable Development

In terms of operational management, the Group continued to enhance its comprehensive risk management framework, with a strengthened focus on collection management of receivables and ex-ante project profitability assessment to reduce working capital tie-up and bad debt risks. It also optimised internal organisational coordination, consolidated product and channel resources across subsidiaries, and improved overall operational efficiency. On the financial side, it strengthened rolling cash flow forecasting, maintained stable bank-enterprise cooperation relationships, and ensured adequate short-term liquidity. At the same time, it continued to enhance its ESG governance framework, incorporating green digitalisation, compliance operations and talent development into its long-term development strategy to improve the Group's sustainable operational capabilities.

Outlook

(I) Industry Environment Outlook

Looking ahead to the second half of 2026, global economic uncertainties are expected to persist, with short-term challenges such as tightened IT budgets of downstream customers, extended project delivery cycles and intensified low-price competition in the industry likely to continue. However, the medium- to long-term development trends of the domestic digital economy, healthcare digitalisation and fintech upgrading remain unchanged. Policies continue to drive the digital transformation of medical institutions and financial institutions, and the market demand for highly intelligent, privacy-preserving and process-automation solutions possesses long-term growth potential. The Group maintains a cautiously optimistic outlook on the long-term development of the industry.

(II) Core Operating Strategy for the Second Half

The Group will continue to pursue its dual-drive development approach of "technological innovation + business model innovation", advancing operations around four core objectives: optimising profit structure, improving cash flow, consolidating technological moats, and broadening market channels:

1. Continuous optimisation of business structure and steady progress towards breakeven

The Group will adhere to the selection of high-margin, low-working-capital, high-quality projects, and continue to divest inefficient loss-making businesses. The Group will strictly implement full-process cost control and continue to reduce non-essential operating expenses. The Group will increase the promotion of standardised software products, raise the proportion of revenue from replicable products, reduce significant capital tie-up from customised projects, continuously narrow operating losses, and strive to gradually achieve operating breakeven. At the same time, the Group will strengthen collection tracking of trade receivables and contract assets, optimise working capital turnover efficiency, and reduce capital tie-up pressure.

2. Strengthening core technology R&D and improving the intellectual property matrix

The Group will continue to invest in R&D across three core tracks: financial RPA and application of intelligent agent technology, healthcare multimodal large models, and privacy-preserving collaborative data computation. The Group will accelerate the commercialisation of invention patents in the healthcare field, and will iterate the standardised software product system, enrich the multi-scenario solution library, and continuously build differentiated technological competitive moats. The Group will leverage existing industry-university-research collaboration platforms to accelerate the industrialisation of cutting-edge technologies, establishing a linkage mechanism between technological innovation and business growth.

3. *Coordinated dual-channel expansion in Chinese Mainland and overseas markets*

In the Chinese Mainland market, the Group will implement a strategy of "deep penetration in core regions + moderate cultivation in emerging industries", cultivate existing advantageous tracks in finance and healthcare, establish a tiered customer operation system, improve localised operational service networks, build a channel partner enablement system, and enhance market coverage density. In overseas markets, the Group will continue to leverage the Hong Kong operations centre to expand Asia-Pacific business and drive the iterative upgrade of existing localised solutions.

4. *Streamlining internal synergy systems and enhancing overall operational resilience*

The Group will deepen the synergy mechanism among subsidiaries, build a cross-entity resource sharing platform, integrate internal and external technology supply chains, and form an innovation resource aggregation capability. The Group will establish a dynamic customer feedback system to iterate product features based on downstream industry demands. The Group will improve talent pipeline development, optimise organisational management efficiency, and continuously strengthen the full-process management system covering market, credit, compliance and geopolitical risks, further enhancing the Group's risk resilience.

(III) Long-term Development Goals

The Group will continue to adhere to its long-term development strategy driven by technological innovation, balancing short-term operating pressures with medium- to long-term value growth, continuously optimising its asset structure, strengthening cash flow management, and steadily improving profitability and operating quality. Leveraging its proprietary core technologies, mature industry solutions, and two-way market presence both domestically and internationally, the Group will seize the long-term opportunities of digital economy transformation and upgrading, steadily enhance its overall competitiveness, and remain committed to creating sustainable and stable long-term value returns for all shareholders.

MANAGEMENT DISCUSSION AND ANALYSIS

Revenue

During the Reporting Period, all of the Group's revenue was derived from its IT solutions services business. This business involves the provision of integrated IT solutions to customers, encompassing software development, technical and maintenance services, sales of standard software products, and other related services, all customised to address their specific requirements.

The Group's IT solutions are categorised into traditional solutions and innovative solutions. Innovative solutions are powered by advanced technologies such as artificial intelligence and big data analytics, and are delivered to customers in key sectors including finance, healthcare and transportation in both customised and standardised formats. Traditional solutions, meanwhile, are primarily utilised in the finance and transportation sectors.

During the Reporting Period, the Group recorded revenue of RMB85.0 million, representing a decrease of 36.4% from RMB133.7 million for the corresponding period of last year. The decrease in the Group's revenue during the Reporting Period was mainly due to lower revenue generated from software development services.

The following analysis sets forth a breakdown of our revenue for the six months ended 30 June 2026 and the corresponding period in 2025, respectively:

Software development services

During the Reporting Period, our revenue from software development services decreased by 40.2% from RMB118.7 million for the corresponding period of last year to RMB71.0 million for the Reporting Period. Among the revenue from software development services, revenue from innovative solutions amounted to RMB42.3 million, accounting for 59.6% of our revenue from software development services. The innovative software development service is a critical component of business revenue of the Group, encompassing a portfolio of advanced products, mainly including robotic process automation (RPA) solutions, medical and healthcare big data intelligent management solutions and others. These innovative products are developed through the application of a range of advanced technologies, including data mining and analysis, cloud-based computing, distributed database management, knowledge graphs, and deep learning, which have successfully served customers in industries such as financial institutions, medical establishments, and large-scale state-owned and privately-owned enterprises in the transportation and logistics industries.

Technical and maintenance services

During the Reporting Period, our revenue from technical and maintenance services amounted to RMB13.2 million, representing an increase of 3.1% from RMB12.8 million in the corresponding period of last year. During the Reporting Period, the revenue from technical and maintenance services accounted for 15.5% of the Group's total revenue.

Sales of standard software

During the Reporting Period, our revenue from sales of standard software amounted to RMB0.8 million, accounting for 0.9% of the total revenue of the Group. Revenue from the innovative solutions amounted to RMB0.8 million, accounting for 100.0% of our revenue from sales of standard software. During the Reporting Period, the Group's innovative solutions that generate revenue through the sales of standard software mainly include products such as the medical quality control and the intelligent healthcare platform.

Cost of sales and services rendered

Our cost of sales and services rendered decreased by 38.6% from RMB109.7 million for the corresponding period of last year to RMB67.4 million for the Reporting Period, mainly due to the decrease in revenue from software development services and the corresponding decrease in related implementation costs.

Gross profit and gross profit margin

Our gross profit decreased from RMB24.1 million in the corresponding period of last year to RMB17.6 million in the Reporting Period. Our gross profit margin increased from 18.0% for the corresponding period last year to 20.7% for the Reporting Period. The decrease in gross profit and increase in gross profit margin were mainly due to the Group's proactive scaling back of, and withdrawal from, certain lower-margin businesses, alongside its strategic focus on higher-margin projects.

Other income and gains

During the Reporting Period, the Group's other income and gains were RMB3.7 million, representing an increase of 2.8% as compared with RMB3.6 million in the corresponding period of last year, primarily due to the increase in bank interest income.

Change in fair value of equity investments at fair value through profit or loss

During the Reporting Period, the Group recorded a loss arising from change in fair value of equity investments at fair value through profit or loss of a total of RMB3.6 million, which was mainly due to fluctuations in the fair value of stocks purchased in the secondary market.

Selling and distribution expenses

Our selling and distribution expenses decreased by 6.2% from RMB9.7 million for the six months ended 30 June 2025 to RMB9.1 million for the six months ended 30 June 2026. The decrease in selling and distribution expenses was mainly due to decreases in staff-related costs and in selling expenses associated with revenue-generating contracts during the Reporting Period.

Administrative expenses

During the Reporting Period, the Group's administrative expenses amounted to RMB21.0 million, representing a decrease of 11.4% as compared with RMB23.7 million in the corresponding period of last year, mainly due to a decrease in staff remuneration, including salaries and allowances.

Research and development expenses

During the Reporting Period, the Group's research and development expenses amounted to RMB18.1 million, representing a decrease of 34.4% as compared with RMB27.6 million in the corresponding period of last year, primarily due to a reduction in the number of research employees and a decrease in the amortisation of the Group's deferred development costs.

Since its listing, the Group has continuously invested heavily in research and development. On the one hand, it has invested in the research and development of corresponding solutions according to the utilization plan of the raised funds; and on the other hand, it has also accelerated in terms of investing heavily in the research and development of technologies related to artificial intelligence and big data analysis. As of 30 June 2026, the Group had a total of 269 items of software copyrights, including 8 items of software copyrights newly formed by developing or upgrading innovative solutions in the six months ended 30 June 2026, accounting for 100.0% of the total 8 items of software copyrights newly developed in the six months ended 30 June 2026.

Other expenses

During the Reporting Period, the Group's other expenses amounted to RMB0.3 million, representing a decrease as compared with RMB2.0 million for the six months ended 30 June 2025, primarily due to decreases in donation expenses and write-down on inventories.

Finance costs

Our finance costs increased from RMB0.5 million for the six months ended 30 June 2025 to RMB0.6 million for the Reporting Period, which remained relatively stable, primarily comprised interest expense on interest-bearing bank borrowings and interest on lease liabilities.

Share of results of an associate

During the Reporting Period, the Group recorded share of loss of an associate of RMB1.4 million, which was due to losses incurred during the Reporting Period by Beijing Heshun Huikang Technology Co., Ltd.(北京和順慧康科技有限公司), an associate invested in by Beijing Neusoft Yuetong Software Technology Co., Ltd.*(北京東軟越通軟件技術有限公司), a subsidiary acquired by the Group.

Loss before tax

As a result of the foregoing, the Group recorded a loss before tax of RMB32.8 million during the Reporting Period, which decreased by RMB31.8 million as compared with the loss before tax of RMB64.6 million in the corresponding period of last year.

Income tax expense

We recorded income tax expense of RMB0.042 million for the Reporting Period, representing an increase of RMB0.018 million as compared with the income tax expense of RMB0.024 million in the corresponding period of last year.

Loss for the six months ended 30 June 2026

Due to the above reasons, we recorded a loss of RMB32.9 million for the six months ended 30 June 2026, which decreased by RMB31.7 million as compared with a loss of RMB64.6 million in the corresponding period of last year.

Non-HKFRS Financial Measures

The interim condensed consolidated financial information has been prepared in accordance with HKFRS Accounting Standards. In evaluating our business, we consider and use adjusted net loss and adjusted EBITDA, which are non-HKFRS financial measures, as supplemental measures to review and assess our operating performance. The presentation of these non-HKFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with HKFRS Accounting Standards. We present these non-HKFRS financial measures because they are used by our management to evaluate our operating performance and formulate business plans. We also believe that the use of these non-HKFRS financial measures facilitates investors' assessment of our operating performance.

These non-HKFRS financial measures are not defined under HKFRS Accounting Standards and are not presented in accordance with HKFRS Accounting Standards. They have limitations as analytical tools and do not reflect all items of income and expense that affect our operations. Further, these non-HKFRS financial measures may differ from those used by other companies, including peer companies, and therefore their comparability may be limited.

We compensate for these limitations by reconciling these non-HKFRS financial measures to the most directly comparable financial measure prepared in accordance with HKFRS Accounting Standards. We encourage you to review our financial information in its entirety and not rely on any single financial measure.

Definition

We define adjusted net loss as loss for the period excluding the effects of the share of results of an associate and change in fair value of equity investments at fair value through profit or loss. We define adjusted EBITDA as adjusted net loss excluding the effects of interest income, interest expense, income tax expense, depreciation of property and equipment, depreciation of right-of-use assets and amortisation of intangible assets.

The following table reconciles our adjusted net loss and adjusted EBITDA, both non-HKFRS financial measures, to loss for the period, being the most directly comparable financial measure calculated and presented in accordance with HKFRS Accounting Standards, for the six months ended 30 June 2026 and 2025, respectively:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Loss for the period	**(32,880)**	(64,633)
Adjustments:		
– Share of results of an associate	**1,422**	1,628
– Change in fair value of equity investments at fair value through profit or loss	**3,609**	18,218
Adjusted net loss (Non-HKFRS Financial Measure)	**(27,849)**	(44,787)
Adjustments:		
– Interest income	**(2,991)**	(1,822)
– Interest expense	**631**	539
– Income tax expense	**42**	24
– Depreciation of property and equipment	**702**	1,203
– Depreciation of right-of-use assets	**2,242**	2,483
– Amortisation of intangible assets	**15,773**	23,698
Adjusted EBITDA (Non-HKFRS Financial Measure)	**(11,450)**	(18,662)

Liquidity, financial and capital resources

During the Reporting Period, we financed our capital expenditure and working capital requirements mainly through cash generated from operations, bank borrowings and net proceeds from the Global Offering and the 2026 Placing. As of 30 June 2026, the Group's total available cash and cash equivalents, including bank balances and time deposits with maturities of less than three months, amounted to RMB230.6 million, compared to RMB283.7 million as at 31 December 2025.

The Group's total bank borrowings as of 30 June 2026 amounted to RMB20.0 million, compared to RMB30.0 million as at 31 December 2025. As at 30 June 2026, all bank borrowings bore interest at a fixed interest rate of 3.2% per annum and were subsequently fully repaid between 9 July 2026 and 26 July 2026. The Group's bank borrowings were strategically deployed to support operational requirements and facilitate business expansion.

Net current assets as of 30 June 2026 were RMB381.0 million, compared to RMB391.9 million as at 31 December 2025, reflecting a decrease of 2.8%. The relatively stable level of net current assets reflected the Group's prudent approach to balancing its liquidity needs and short-term obligations while maintaining sufficient resources to support its business development.

Exposure to exchange rate fluctuation

For the six months ended 30 June 2026, the functional currency of companies operating in the PRC is Renminbi. Most of the Group's monetary assets were mainly denominated in US dollars and Renminbi. We manage foreign exchange risk by performing periodic reviews of our net foreign exchange exposures and try to minimise these exposures through natural hedges. We operate mainly in the PRC with most of the transactions settled in Renminbi. The management considers that the business is not exposed to any significant foreign exchange risk as there are no significant financial assets or liabilities denominated in currencies other than the respective functional currencies of our entities. During the Reporting Period, the Group did not enter into any hedging transaction against foreign currency risks.

Commitments

The Group has various contracted, but not provided for short-term lease commitments as of 30 June 2026. The future lease payments for these non-cancellable lease contracts are RMB0.5 million (as at 31 December 2025: future lease payments of RMB1.1 million for such non-cancellable lease contracts) and due within one year.

Contingent liabilities

As of 30 June 2026, we did not have any material contingent liability, guarantee or any litigation or claim of material importance, pending or threatened against any member of our Group.

Future plans for material investments and capital assets

Save as disclosed in this announcement, the Group did not have future plans for material investments and capital assets as of 30 June 2026.

Material acquisitions and disposals of subsidiaries and affiliated companies

For the six months ended 30 June 2026, the Group did not have any material acquisitions or disposals of subsidiaries and affiliated companies.

Significant investments

As of 30 June 2026, we did not hold any significant investments representing 5% or more of the Group's total assets as of 30 June 2026.

Charges on the Group's assets

As of 30 June 2026, the Group had no charges on its assets.

Customer credit risk

Our business operations are subject to the risk of payment deferrals and/or defaults by our customers. For our software development services, most of our contracts provide for periodic installments from our customers based on project milestones, such as delivery, installation and testing of our solutions. However, we incur costs associated with a project, primarily including staff costs relating to project execution and software development, electronic equipment and certain project implementation expenses, on an ongoing basis from the beginning. As a result, we are required to make prepayments for certain project costs and expenses before receiving sufficient payments from our customers.

During the Reporting Period, the Group typically granted its customers a credit period depending on the relevant contract terms and its evaluation of the customers' creditworthiness. In determining the actual length of credit terms granted to a specific customer, we consider various factors such as reputation, length of business relationship and past payment records. As of 30 June 2026, our trade receivables amounted to RMB289.6 million and an allowance for expected credit losses of RMB101.6 million was recognized against such balance. We are thus exposed to the risk that customers may delay or even be unable to pay when milestones are reached or upon completion of contracts. This may put our cash flow and working capital under pressure.

1. ***The subsequent settlements are set out below in relation to the trade receivables as at 30 June 2026:***

Ageing	**Gross amount** *RMB'000*	**Subsequent settlement** *RMB'000*
Within 180 days	46,391	7,278
181 days to 1 year	42,879	1,695
1 year to 2 years	48,599	159
2 years to 3 years	36,882	439
Over 3 years	114,831	1,561
Total	**289,582**	**11,132**

2. ***Recoverability of long-aged receivables and reasons why the loss allowances were adequate***

   (1) Customers with strong creditworthiness

   The trade receivable balance of the Group as of 30 June 2026 was mainly from large customers with good reputations and strong creditworthiness, the majority of which were Chinese state-owned enterprises and listed public companies, including top-tier banks, trust companies, asset management companies, Class III Grade A hospitals, railway bureaus, locomotive depots, railway information technology companies, railway bureau groups, airlines, aviation food companies, aviation materials companies, etc. Such customers are in good standing and have strong creditworthiness and bargaining power, and have stringent and extensive internal payment and settlement processes, which often require time-consuming internal approval processes before payments are made, resulting in further extension of their payment cycles. As of 30 June 2026, 73.2% of the trade receivable balance was recorded from Chinese state-owned enterprises and listed public companies.

   In addition, the balance of trade receivables over 180 days as of 30 June 2026 was mainly recorded from Chinese state-owned enterprises and listed public companies with which the Group had longstanding cooperation, and there has been no recoverability issue in relation to trade receivables in previous years and both parties have maintained a good cooperation relationship.

(2) *The balance of trade receivables over 1 year remains in a trend of continuous collection of receivables*

As of 30 June 2026, the balance of trade receivables over 1 year amounted to RMB200.3 million, recorded from a total of 125 customers, among which 119 customers are still performing contracts with the Group so far, and the Group has continued to collect receivables since 30 June 2026.

(3) *The business model and customer base of the Group remain sound amid ongoing optimisation*

In relation to trade receivables, while the business model and the customer base of the Group have remained substantially consistent, with the fundamental basis disclosed in the prospectus of the Company dated 21 December 2020 remaining solid, the Group has continued to pursue structural optimisation at the operational level. The Group has proactively shifted its business focus towards higher-value-added areas, with the primary objective of improving the quality of its trade receivables.

The Company considers that it has entered into normal business arrangements with these customers. To date, the Group has not identified any material issues requiring adjustments to the current level of provision for impairment of trade receivables. Management is of the view that the existing provision for impairment is adequate and sufficient to cover the expected credit losses based on the Group's assessment under the applicable accounting standards.

3. Actions taken or to be taken to recover such long-outstanding receivables

The Group has continued to (1) increase sales revenue from customers with short payment cycles and gradually reduce sales to customers with long payment cycles to achieve substantial improvements against the long payment cycle of trade receivables; (2) maintain strict control over its outstanding trade receivables and have a credit control department to minimise the credit risk. The Group has strictly followed its credit management policy and will continue to follow the steps and measures stipulated in the credit management policy to manage the trade receivables and maintain the working capital. As required by the credit management policy of the Group, the Group has instructed designated sales personnel to follow up directly with their responsible customers, and the sales and marketing staff of the Group make collection calls to customers whose bills have been overdue for less than 90 days; for customers whose bills have been overdue within 90 to 360 days, the sales and marketing staff escalate the matter to the business department and both the sales and marketing staff and the business department make collection calls to the customers; and for customers whose bills have been overdue for more than 360 days, the Group assigns the sales and marketing staff to visit the customers for face-to-face communication, and the sales and marketing staff and business departments continue to follow up with and make collection calls to customers. For customers with extended payment cycles or non-compliant repayment practices, the Company will initiate legal proceedings or arbitration procedures on a case-by-case basis. To manage the trade receivables, the Group has also strengthened the cooperation between the technical team and the sales and marketing team to conduct more efficient collection, and taken into account the collection speed in the performance assessment of the employees. In addition, the Group will continue to issue periodic written payment reminders to the customers. Overdue balances are also regularly reviewed by the senior management; and (3) regularly make enquiries on customers' ratings and make an analysis of the background, reputation, market position and the operating conditions of customers based on publicly available information.

Key Financial and Business Performance Indicator

The key financial and business performance indicator comprises return on equity.

Our return on equity increased from -9.6% in the six months ended 30 June 2025 to -6.3% in the six months ended 30 June 2026, primarily due to the decrease in the amount of loss recorded for the Reporting Period.

Gearing ratio

The Group's gearing ratio decreased from 5.5% as at 31 December 2025 to 3.9% as at 30 June 2026, primarily due to the decrease in bank borrowings. The calculation of gearing ratio is based on total borrowings divided by total equity as of the period end and multiplied by 100.0%.

Employees, Training and Remuneration Policies

As of 30 June 2026, the Group had 604 employees, representing a decrease of 60 employees compared to the same period of last year. The staff costs including Directors' emoluments were approximately RMB75.2 million for the Reporting Period.

Remuneration of the Group's employees includes basic salary, bonuses and cash subsidies. We determine our employees' compensation based on each employee's performance, seniority, position and qualifications.

We adopted the Post-IPO Share Option Scheme on 5 December 2020, which falls within the ambit of, and is subject to, the regulations under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). The purpose of the Post-IPO Share Option Scheme is to provide incentives and rewards to eligible persons for their contribution to, and continuing efforts to promote the interests of the Group.

We recognize the importance of keeping the Directors updated with the latest information on the duties and obligations of a Director of a company whose shares are listed on the Stock Exchange and the general regulatory and environmental requirements applicable to such a listed company. To meet this goal, we are committed to our employees' continuing education and development. We provide pre-employment and regular continuing training to our employees, which we believe is effective in equipping them with the skill set and work ethics that we require. Also, we continuously provide comprehensive training to our technical staff, equipping them with knowledge and skills to perform a variety of functions on different projects and allowing us to quickly find a qualified and suitable replacement internally in the event of an employee's resignation.

OTHER INFORMATION

USE OF PROCEEDS FROM THE GLOBAL OFFERING

The Shares of the Company were listed on the Main Board of the Stock Exchange on 6 January 2021, whereby 200,000,000 new Shares were issued at the offer price of HK$4.36 per share by the Company. After deduction of the underwriting fees, commissions and other related costs and expenses, the net proceeds from the Global Offering of the Company amounted to approximately HK$790.4 million (representing net proceeds of HK$3.952 per new Share) (the "**IPO Proceeds**").

In order to better utilize the financial resources of the Group and to capture favourable investment opportunities, the Board has reviewed the utilization of the IPO Proceeds and resolved to reallocate not more than HK$71.0 million of the surplus to pay the equity transfer consideration, to make the capital increase payment and to fulfill or pay capital contribution obligations for the acquisition of Neusoft Yuetong (the "**Re-allocation**"). For further details, please refer to the announcement of the Company dated 20 June 2022.

On 23 September 2024, after due and careful consideration on the prevailing business environment and development needs of the Group, the Board resolved to change the use of the unutilized IPO Proceeds to (i) reallocate the unutilized surplus of approximately HK$49.2 million for working capital and other general corporate purposes; and (ii) build on the Group's long-standing accumulated capabilities in independent research and development, capabilities in technological innovation, industry insights and customer needs, the Company will further enhance the original plan for developing new solutions and upgrading existing solutions by increasing the related investment plans for the development of innovative universal products and the development of innovative financial products, and will further reallocate the original plan of IPO Proceeds for developing new solutions and upgrading existing solutions: (a) approximately HK$38.9 million will be utilized to develop innovative universal products; and (b) approximately HK$20.0 million will be utilized to develop innovative financial products (the "**Further Re-allocation**"). For details, please refer to the announcement of the Company dated 23 September 2024.

The following table sets forth the details of the use of the IPO Proceeds during the Reporting Period:

	Original allocation of the IPO Proceeds (approximate)		Allocation of IPO Proceeds after the First Re-allocation (approximate)		Further Re-allocation of the Unutilized IPO Proceeds (approximate)		Unutilized amount as of 1 January 2026	Utilized amount during the Reporting Period	Unutilized amount as of 30 June 2026	Expected timeline for the use of unutilized proceeds[(1)]
	Percentage	Amount	Percentage	Amount	Percentage	Amount				
		HK$ million		*HK$ million*		*HK$ million*	*HK$ million*	*HK$ million*	*HK$ million*	
For developing new solutions and upgrading existing solutions	**80.0%**	**632.3**	**72.8%**	**575.5**	**69.4%**	**144.8**	**36.8**	**16.8**	**20.0**	
– to develop and upgrade the Group's medical quality control and safety warning system	20.0%	158.1	18.2%	143.9	11.7%	24.4	11.5	4.8	6.7	By December 2026
– to develop the Group's clinical pathway management system	20.0%	158.1	18.2%	143.9	11.6%	24.2	8.8	3.4	5.4	By December 2026
– to develop the Group's telemedicine system	10.0%	79.0	9.1%	71.9	3.5%	7.3	3.9	0.3	3.6	By December 2026
– to develop a new solution of intelligent healthcare platform	10.0%	79.0	9.1%	71.9	6.1%	12.7	6.8	2.5	4.3	By December 2026
– to upgrade the Group's RPA solution	20.0%	158.1	18.2%	143.9	8.3%	17.3	0	0	0	N/A
– to develop innovative universal products	–	–	–	–	18.6%	38.9	0	0	0	N/A
– to develop innovative financial products	–	–	–	–	9.6%	20.0	5.8	5.8	0	N/A
For enhancing the Group's sales and marketing efforts	**10%**	**79.1**	**9.1%**	**72.0**	**7.0%**	**14.7**	0	0	0	N/A
For working capital and other general corporate purposes	**10%**	**79.0**	**9.1%**	**71.9**	**23.6%**	**49.2**	0	0	0	N/A
Funds proposed to be used for the Neusoft Yuetong Acquisition	**–**	**–**	**9.0%**	**71.0**	**–**	**–**	0	0	0	N/A
Total	**100%**	**790.4**	**100%**	**790.4**	**100%**	**208.7**	**36.8**	**16.8**	**20.0**	

Notes:

(1) Due to the Further Re-allocation and the adjustment of arrangements based on the Group's R&D progress, the Company expects the Unutilized IPO Proceeds will be fully utilized by December 2026 except for the Unutilized IPO Proceeds re-allocated for working capital and other general corporate purposes, which are expected to be fully utilized by December 2027. The expected timeline for utilizing the unutilized funds is based on the Group's best estimation of future market condition. It may be subject to change based on the current and future development of market conditions.

(2) Any discrepancy arising in the decimal figures in the table above is due to the effect of rounded figures.

(3) The utilization of IPO Proceeds for developing new solutions and upgrading existing solutions after the Further Re-allocation still includes the balance of the relevant unutilized IPO Proceeds of approximately HK$63.2 million originally planned for office lease, purchase and renovation for IT solutions as disclosed in the Prospectus.

The Company has utilized, and will continue to utilize the IPO Proceeds in accordance with the intended purposes as set out in the Prospectus and the announcements of the Company dated 20 June 2022 and 23 September 2024.

USE OF PROCEEDS FROM THE 2026 PLACING

On 4 February 2026 (after trading hours), the Company entered into a placing agreement with Dongxing Securities (Hong Kong) Company Limited (the "**Placing Agent**"), pursuant to which the Company conditionally agreed to place through the Placing Agent, on a best effort basis, a maximum of 60,000,000 ordinary shares of par value US$0.000001 each, with an aggregate nominal value of US$60, at the placing price of HK$0.30 per placing share (the "**2026 Placing**"). The 2026 Placing was completed on 11 February 2026, and a total of 60,000,000 shares of the Company were placed to Blossoming M Holdings Limited (the "**Placee**"). The placing price of HK$0.30 per placing share represented a premium of approximately 48.51% to the closing price of HK$0.202 per share as quoted on the Stock Exchange on 4 February 2026, being the date of the placing agreement. The gross proceeds and net proceeds (after deducting the placing commission and other related expenses) from the 2026 Placing amounted to HK$18,000,000 and HK$17,909,270, respectively, and the net price per placing share was approximately HK$0.298. The Board considered that the 2026 Placing represented an opportunity to raise capital for the Company while broadening its shareholder and capital base, and would strengthen the financial position of the Group and provide additional working capital to the Group for its long-term development and growth.

Use of the net proceeds from the 2026 Placing during the Reporting Period is set out in the table below:

Intended use	Allocation	Net proceeds	Utilized amount during the Reporting Period	Unutilized amount as of 30 June 2026	Expected timeline for the use of unutilized net proceeds
	%	*HK$ million*	*HK$ million*	*HK$ million*	
Replenishment of general working capital					
– Professional fees	20%	3.6	3.6	0	N/A
– Employee salaries	60%	10.7	10.7	0	N/A
– Utility expenses and other costs	20%	3.6	3.6	0	N/A
Total	**100%**	**17.9**	**17.9**	**0**	**N/A**

Note: Any discrepancy arising in the decimal figures in the table above is due to the effect of rounded figures.

The Company has utilized the net proceeds from the 2026 Placing in accordance with the intended purposes as set out in the announcement of the Company dated 4 February 2026.

MEMORANDUM OF UNDERSTANDING REGARDING POTENTIAL EQUITY ACQUISITION

The Company entered into a memorandum of understanding regarding the potential acquisition of the entire equity interest of HK Ant Global Investment Co., Limited with the company, its shareholders and beneficial owners on 22 May 2026 (the "**Memorandum**"). The exclusivity period under the Memorandum shall commence from the date of signing of the Memorandum and continue until the date of signing of the acquisition agreement or the date falling ninety days after the date of the Memorandum (i.e. 20 August 2026), whichever is earlier. As at the date of this announcement, the parties have not entered into a formal acquisition agreement. For details, please refer to the announcements of the Company dated 22 May 2026 and 25 May 2026.

COMPLIANCE WITH CORPORATE GOVERNANCE CODE

The Group is committed to maintaining high standards of corporate governance. The Board believes that good corporate governance standards are essential in providing a framework for the Company to safeguard the interests of its shareholders and corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

Pursuant to code provision C.2.1 of Part 2 of the Corporate Governance Code (the "**CG Code**") as set out in Appendix C1 to the Listing Rules, companies listed on the Stock Exchange are expected to comply with, but may choose to deviate from the requirement that the responsibilities between the chairman and the chief executive officer should be segregated and should not be performed by the same individual. The roles of the Chairman and the Chief Executive Officer are held by Mr. Zhai Shuchun ("**Mr. Zhai**"). With extensive experience in the information technology industry, Mr. Zhai is responsible for the overall strategic planning and general management of the Group and is instrumental to our growth and business expansion. The Board considers that vesting the roles of chairman and chief executive officer in the same person is beneficial to the management of the Group and ensures consistent leadership within the Group and enables more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority will not be impaired and this structure will enable the Company to make and implement decisions promptly and effectively. In light of the above, the Board considers that the deviation from code provision C.2.1 of the CG Code is appropriate in the circumstances of the Company.

The Company has adopted all the applicable principles and code provisions set out in the CG Code as the basis of the Group's corporate governance practices. Save as disclosed in this announcement, the Group has complied with the CG Code throughout the six months ended 30 June 2026. The Company will periodically review its corporate governance policies and will propose any amendment, if necessary, to ensure compliance with the CG Code effective from time to time.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as the code of conduct of the Company regarding Directors' securities transactions. Having made specific enquiries of all the Directors, each of the Directors has confirmed that he/she has complied with the requirements of the Model Code for the six months ended 30 June 2026.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries had purchased, sold, or redeemed any of the Company's listed securities (including sale of treasury shares) during the Reporting Period.

As of 30 June 2026, the Company had 5,952,800 treasury shares (as defined under the Listing Rules) which are intended to be used for purposes such as employee incentives, sale or transfer to obtain liquid funds subject to the actual decision(s) of the Board.

AUDIT COMMITTEE AND REVIEW OF FINANCIAL STATEMENTS

The audit committee of the Board (the "**Audit Committee**") was established with written terms of reference in compliance with the CG Code. The Audit Committee comprises three independent non-executive Directors, namely, Mr. You Linfeng (the chairman of the Audit Committee), Mr. Tang Baoqi and Ms. Yang Juan.

The financial information for the six months ended 30 June 2026 set out in this announcement is unaudited but has been reviewed by the Company's external auditor, Forvis Mazars CPA Limited, in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" and by the Audit Committee. The Audit Committee has reviewed the interim results and was satisfied that the Company's unaudited financial information contained in this announcement was prepared in accordance with applicable accounting standards.

The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group, and discussed matters in relation to, among others, risk management, internal control and financial reporting of the Group with management and the Company's external auditor. The Audit Committee is of the view that the interim financial results for the six months ended 30 June 2026 have complied with relevant accounting standards, rules and regulations, and have been officially and properly disclosed.

INTERIM DIVIDENDS

The Board has resolved not to declare the payment of interim dividends for the six months ended 30 June 2026 to the shareholders.

SUBSEQUENT EVENTS

No significant event of the Group has occurred subsequent to 30 June 2026 and up to the date of this announcement.

PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM REPORT

This announcement is published on the website of the Stock Exchange (www.hkexnews.hk) and the Company's website (www.newlinktech.com.cn). The interim report of the Company for the six months ended 30 June 2026 will be published on the aforesaid websites in due course.

APPRECIATION

On behalf of the Board, I would like to thank all our colleagues for their diligence, dedication, loyalty and integrity. I would also like to thank all our shareholders, customers, bankers and other business associates for their trust and support.

By order of the Board
Newlink Technology Inc.
ZHAI Shuchun
Chairman of the Board and Chief Executive Officer

Beijing, the PRC, 25 August 2026

As at the date of this announcement, the executive Directors are Mr. ZHAI Shuchun, Ms. QIN Yi and Mr. LI Xiaodong; and the independent non-executive Directors are Mr. TANG Baoqi, Ms. YANG Juan and Mr. YOU Linfeng.

* *For identification purposes only*